---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-013677"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:51:11.870480+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial

## Summary
- First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.
- Phase 1 trial is a feasibility and safety study in up to 10 patients under an FDA-approved IND, with three active clinical sites.
- Primary endpoint: establishment of a continuous biological neoconduit by three months post-surgery; secondary: mucosal lining by 12 months.
- CEI combines a polyurethane scaffold with autologous adipose-derived mesenchymal stromal cells; scaffold removed endoscopically at 21-42 days.

## SEC filing metadata
- accession: 0001437749-26-013677
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000143774926013677/0001437749-26-013677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000143774926013677/hrgn20260427_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-013677
- JSON: https://secwatch.observer/filing/0001437749-26-013677.json
- Plain text: https://secwatch.observer/filing/0001437749-26-013677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.